California Public Employees Retirement System maintained its position in Pfenex Inc. (NYSEAMERICAN:PFNX) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,000 shares of the biotechnology company’s stock at the close of the 2nd quarter. California Public Employees Retirement System owned approximately 0.28% of Pfenex worth $261,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in PFNX. LMR Partners LLP acquired a new position in Pfenex during the second quarter worth about $252,000. Goldman Sachs Group Inc. raised its position in Pfenex by 126.7% during the first quarter. Goldman Sachs Group Inc. now owns 56,020 shares of the biotechnology company’s stock worth $325,000 after acquiring an additional 31,308 shares during the last quarter. Legal & General Group Plc raised its position in Pfenex by 2,567.5% during the second quarter. Legal & General Group Plc now owns 110,249 shares of the biotechnology company’s stock worth $442,000 after acquiring an additional 106,116 shares during the last quarter. Bank of America Corp DE raised its position in Pfenex by 2,736.1% during the first quarter. Bank of America Corp DE now owns 80,289 shares of the biotechnology company’s stock worth $467,000 after acquiring an additional 77,458 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Pfenex by 249.0% during the first quarter. Dimensional Fund Advisors LP now owns 94,809 shares of the biotechnology company’s stock worth $551,000 after acquiring an additional 67,640 shares during the last quarter.

Pfenex Inc. (PFNX) traded down $0.14 during trading hours on Wednesday, hitting $2.60. 69,300 shares of the stock were exchanged, compared to its average volume of 114,652. Pfenex Inc. has a twelve month low of $2.54 and a twelve month high of $10.00.

Pfenex (NYSEAMERICAN:PFNX) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.17. The business had revenue of $5.02 million during the quarter, compared to analyst estimates of $3.30 million. Pfenex had a negative net margin of 175.52% and a negative return on equity of 63.57%. The company’s revenue was down 89.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.46 earnings per share.

A number of equities analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of Pfenex from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 15th. JMP Securities cut their price objective on shares of Pfenex from $21.00 to $8.00 and set an “outperform” rating for the company in a research report on Friday, November 10th. ValuEngine lowered shares of Pfenex from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Finally, William Blair reissued an “outperform” rating on shares of Pfenex in a research report on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and one has given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $5.50.

COPYRIGHT VIOLATION WARNING: “Pfenex Inc. (PFNX) Holdings Held by California Public Employees Retirement System” was first published by Daily Political and is the property of of Daily Political. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/11/29/pfenex-inc-pfnx-holdings-held-by-california-public-employees-retirement-system.html.

Pfenex Profile

Pfenex Inc is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab).

Want to see what other hedge funds are holding PFNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfenex Inc. (NYSEAMERICAN:PFNX).

Institutional Ownership by Quarter for Pfenex (NYSEAMERICAN:PFNX)

Receive News & Ratings for Pfenex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex Inc. and related companies with MarketBeat.com's FREE daily email newsletter.